Total Occlusions: Device Obstacle or Opportunity?
This article was originally published in Start Up
Executive Summary
The market is promising for using catheters, instead of surgery, to open vascular blockages. But the right technology remains elusive.
You may also be interested in...
Avinger: Finally, Seeing Through Total Occlusions, But Will Clinical Value Generate Economic Return?
Noted physician/entrepreneur John Simpson is back. His latest company, Avinger, has finally achieved his long-sought goal: combining imaging and therapeutics in catheter technology for crossing CTOs. Will clinical innovation be enough to reward Avinger in an increasingly economically focused medtech world?
FlowCardia: Playing it Safe in Total Occlusions
Chronic total occlusions remain one of the most significant challenges and opportunities facing interventional cardiologists and radiologists. FlowCardia is looking to succeed where other device companies have failed by emphasizing safety and simplicity.
FlowCardia: Playing it Safe in Total Occlusions
Chronic total occlusions remain one of the most significant challenges and opportunities facing interventional cardiologists and radiologists. FlowCardia is looking to succeed where other device companies have failed by emphasizing safety and simplicity.